Skip to main content Back to Top
Advertisement

7/12/2021

Melphalan Injection

Products Affected - Description

    • Alkeran powder for solution for injection, Apo-Pharma, 50 mg, vial, 1 count, NDC 52609-3001-00
    • Melphalan powder for solution for injection, Fresenius Kabi, 50 mg, vial, 1 count, NDC 63323-0760-20
    • Melphalan powder for solution for injection, Mylan Institutional, 50 mg, vial, 1 count, NDC 67457-0195-01
    • Melphalan powder for solution for injection, Par Pharmaceuticals, 50 mg, vial, 1 count, NDC 42023-0129-01 - discontinued
    • Melphalan powder for solution for injection, Teva, 50 mg, vial, 1 count, NDC 45963-0686-02

Reason for the Shortage

    • Apo-Pharma did not provide a reason for the shortage.
    • Athenex has melpalan available.
    • Dr. Reddy's has melphalan injection available.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Meitheal has melphalan injection available.
    • Mylan Institutional did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • Spectrum has Evomela injection available.

Available Products

    • Evomela powder for solution for injection, Spectrum, 50 mg, vial, 1 count, NDC 68152-0109-00
    • Melphalan powder for solution for injection, Athenex, 50 mg, vial, 1 count, NDC 70860-0214-61
    • Melphalan powder for solution for injection, Dr. Reddy's, 50 mg, vial, 1 count, NDC 43598-0392-48
    • Melphalan powder for solution for injection, Meitheal Pharmaceuticals, 50 mg, vial, 1 count, NDC 71288-0112-90

Estimated Resupply Dates

    • Apo-Pharma has Alkeran 50 mg vials on back order and the company cannot estimate a release date.
    • Fresenius Kabi has melphalan 50 mg vials on back order and the company estimates a release date of late-August to early-September 2021.
    • Mylan Institutional has melphalan 50 mg vials on back order and the company estimates a release date of early-July 2021.
    • Teva has melphalan 50 mg vials on back order and the company estimates a release date of July 2021.

Updated

Updated July 12, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 28, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.